Table 1 Patient Characteristics
XM02 (n = 140) | Neupogen™ (n = 136) | Placebo/XM02* (n = 72) | |
|---|---|---|---|
Gender [N (%)] | |||
Male | 1 (0.7%) | 1 (0.7%) | - |
Female | 139 (99.3%) | 135 (99.3%) | 72 (100.0%) |
Age [years] | |||
Mean | 51.0 | 51.4 | 49.5 |
SD | 9.7 | 10.7 | 10.3 |
Median | 51.0 | 51.0 | 48.0 |
Range | 25–75 | 28–74 | 28–74 |
Race [N (%)] | |||
Caucasian | 120 (85.7%) | 118 (86.8%) | 62 (86.1%) |
Black | 1 (0.7%) | 5 (3.7%) | 2 (2.8%) |
Hispanic | 10 (7.1%) | 10 (7.4%) | 6 (8.3%) |
Other | 9 (6.4%) | 3 (2.2%) | 2 (2.8%) |
Body Mass Index [kg/m 2 ] | |||
Mean | 27.77 | 28.20 | 27.42 |
SD | 6.11 | 5.70 | 6.02 |
Median | 27.55 | 26.90 | 27.30 |
Range | 16.2–56.2 | 15.9–45.4 | 17.0–41.3 |
Cancer stage [N (%)] | |||
High risk stage II | 23 (16.4%) | 36 (26.5%) | 15 (20.8%) |
Stage III | 79 (56.4%) | 69 (50.7%) | 38 (52.8%) |
Stage IV | 38 (27.1%) | 31 (22.8%) | 19 (26.4%) |
Therapy [N (%)] | |||
Adjuvant | 96 (68.6%) | 96 (70.6%) | 47 (65.3%) |
Metastatic | 44 (31.4%) | 40 (29.4%) | 25 (34.7%) |
Prior radiation therapy [N (%)] | |||
No | 125 (89.3%) | 127 (93.4%) | 63 (87.5%) |
Yes | 15 (10.7%) | 9 (6.6%) | 9 (12.5%) |